Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esther Serra

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Frontiers in Immunology|March 30, 2023
Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patientsLídia Sans-de San Nicolàs, Ignasi Figueras-Nart, Irene García-Jiménez, et al.
Lancet (London, England)|July 21, 2024
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trialsRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
The British Journal of Dermatology|March 30, 2023
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trialsAndrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, et al.
International Journal of Dermatology|June 2, 2025
Clinical Characteristics, Diagnostic Approaches, Therapeutic Management, and Associated Comorbidities of Prurigo Nodularis (Chronic Nodular Prurigo): An Observational Study in Clinical Practice in SpainJosé Carlos Armario-Hita, Jose Juan Pereyra-Rodriguez, Francisco Javier de Ortiz de Frutos, et al.
Journal of the American Academy of Dermatology|March 13, 2025
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trialsMelinda Gooderham, Sonja Molin, Robert Bissonnette, et al.
Dermatology and Therapy|April 21, 2026
Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart ReviewEnrique Gómez de la Fuente, Enrique Herrera, Iñigo Martinez-Espronceda Esquerdo, et al.
Journal of the American Academy of Dermatology|August 19, 2018
Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trialSabine Steinke, Claudia Zeidler, Claudia Riepe, et al.
International Journal of Dermatology|October 19, 2024
Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter studyJose Carlos Armario-Hita, Jose Juan Pereyra-Rodriguez, Alicia González-Quesada, et al.
Clinical and Experimental Dermatology|April 25, 2023
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety resultsJosé-Juan Pereyra-Rodríguez, Pedro Herranz, Ricardo Ruiz-Villaverde, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|March 31, 2023
Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in SpainAlexandre Docampo-Simón, María J Sánchez-Pujol, Maria A Pastor-Nieto, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Frontiers in Immunology|March 30, 2023
Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patientsLídia Sans-de San Nicolàs, Ignasi Figueras-Nart, Irene García-Jiménez, et al.
Lancet (London, England)|July 21, 2024
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trialsRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
The British Journal of Dermatology|March 30, 2023
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trialsAndrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, et al.
International Journal of Dermatology|June 2, 2025
Clinical Characteristics, Diagnostic Approaches, Therapeutic Management, and Associated Comorbidities of Prurigo Nodularis (Chronic Nodular Prurigo): An Observational Study in Clinical Practice in SpainJosé Carlos Armario-Hita, Jose Juan Pereyra-Rodriguez, Francisco Javier de Ortiz de Frutos, et al.
Journal of the American Academy of Dermatology|March 13, 2025
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trialsMelinda Gooderham, Sonja Molin, Robert Bissonnette, et al.
Dermatology and Therapy|April 21, 2026
Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart ReviewEnrique Gómez de la Fuente, Enrique Herrera, Iñigo Martinez-Espronceda Esquerdo, et al.
Journal of the American Academy of Dermatology|August 19, 2018
Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trialSabine Steinke, Claudia Zeidler, Claudia Riepe, et al.
International Journal of Dermatology|October 19, 2024
Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter studyJose Carlos Armario-Hita, Jose Juan Pereyra-Rodriguez, Alicia González-Quesada, et al.
Clinical and Experimental Dermatology|April 25, 2023
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety resultsJosé-Juan Pereyra-Rodríguez, Pedro Herranz, Ricardo Ruiz-Villaverde, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|March 31, 2023
Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in SpainAlexandre Docampo-Simón, María J Sánchez-Pujol, Maria A Pastor-Nieto, et al.
Pageof 6